Company Filing History:
Years Active: 1992-1996
Title: Howard E. Smith: Innovator in Radiopharmaceuticals
Introduction
Howard E. Smith is a notable inventor based in Nashville, TN (US). He has made significant contributions to the field of nuclear medicine, particularly in the development of radiopharmaceuticals. With a total of 2 patents, his work focuses on innovative imaging agents that enhance the detection and analysis of brain functions.
Latest Patents
Smith's latest patents include groundbreaking work on radioiodinated benzamines and their methods of use as radioimaging agents. These novel, substituted benzamides in radioiodinated form are essential in radiopharmaceutical compositions. They serve as imaging agents to detect, visualize, and analyze the distribution and function of the dopamine D2 receptor in the mammalian brain. The specific combination of lipophilicity and dopamine D2 receptor affinity in these compounds is crucial for achieving the required image contrast. The iodinated benzamides can be synthesized by reacting a trialkyltin substituted benzamide with an acid in the presence of radioactive iodine, generated through in situ oxidation of an appropriate iodide nuclide salt.
Career Highlights
Howard E. Smith is affiliated with Vanderbilt University, where he continues to advance research in radiopharmaceuticals. His innovative approaches have positioned him as a key figure in the field, contributing to the understanding of brain functions through advanced imaging techniques.
Collaborations
Smith has collaborated with esteemed colleagues such as Tomas De Paulis and Robert M. Kessler. These partnerships have further enriched his research and development efforts in the realm of nuclear medicine.
Conclusion
Howard E. Smith's contributions to the field of radiopharmaceuticals exemplify the impact of innovative thinking in medical science. His patents and ongoing research continue to pave the way for advancements in imaging technologies that enhance our understanding of the human brain.